• Revenue increased by 9% to $42.6 million
• Net profit after tax rose 566% to $0.6 million
• Pain Management revenue up 21%, driven by volume growth
• Respiratory revenue down 15% due to softer demand
• Strong cash flow generation with operating cash flow up $5.8 million

Medical Developments International Ltd reported strong financial results for the year ended 30 June 2026. Revenue increased by 9% to $42.6 million, with Pain Management revenue up 21% driven by volume growth in all markets and higher pricing in Australia. In contrast, Respiratory revenue declined 15%, primarily due to softer demand. Net profit after tax rose significantly by 566% to $0.6 million. The company also saw improvements in operating cash flow, up $5.8 million, and free cash flow, up $5.8 million. The company's strategic focus for FY27 includes increasing Penthrox penetration in existing markets, expanding into new markets, and enhancing margins through operational efficiencies.

FY27 revenue expected to be higher due to increased Penthrox demand

The Group expects higher in-market Penthrox demand in FY27, supported by the paediatric indication in Europe and recent health economic data. Stable demand is expected in the Respiratory segment. The impact of Middle East supply chain disruption and US tariffs remains uncertain.